These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 16154196

  • 21. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study.
    Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A.
    Ophthalmology; 2012 Jun; 119(6):1184-9. PubMed ID: 22424833
    [Abstract] [Full Text] [Related]

  • 22. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
    Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, BRAVO Investigators.
    Ophthalmology; 2010 Jun; 117(6):1102-1112.e1. PubMed ID: 20398941
    [Abstract] [Full Text] [Related]

  • 23. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.
    Domalpally A, Ip MS, Ehrlich JS.
    Ophthalmology; 2015 Apr; 122(4):779-86. PubMed ID: 25601535
    [Abstract] [Full Text] [Related]

  • 24. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.
    Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, Boos CJ, Xing W, Egan C, Peto T, Bunce C, Leslie RD, Hykin PG.
    Ophthalmology; 2010 Jun; 117(6):1078-1086.e2. PubMed ID: 20416952
    [Abstract] [Full Text] [Related]

  • 25. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY.
    Maturi RK, Bleau L, Saunders J, Mubasher M, Stewart MW.
    Retina; 2015 Aug; 35(8):1604-14. PubMed ID: 25829346
    [Abstract] [Full Text] [Related]

  • 26. Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema.
    Querques G, Bux AV, Martinelli D, Iaculli C, Noci ND.
    Acta Ophthalmol; 2009 Sep; 87(6):623-30. PubMed ID: 19678810
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
    Ruiz-Moreno JM.
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
    [Abstract] [Full Text] [Related]

  • 30. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema.
    Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA.
    Am J Ophthalmol; 2006 Dec; 142(6):961-9. PubMed ID: 17046701
    [Abstract] [Full Text] [Related]

  • 31. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial.
    Sutter FK, Simpson JM, Gillies MC.
    Ophthalmology; 2004 Nov; 111(11):2044-9. PubMed ID: 15522370
    [Abstract] [Full Text] [Related]

  • 32. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.
    Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA.
    Ophthalmology; 2014 Jul; 121(7):1414-1420.e1. PubMed ID: 24679444
    [Abstract] [Full Text] [Related]

  • 33. Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab.
    Sophie R, Lu N, Campochiaro PA.
    Ophthalmology; 2015 Jul; 122(7):1395-401. PubMed ID: 25870079
    [Abstract] [Full Text] [Related]

  • 34. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
    Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY, CRUISE Investigators.
    Ophthalmology; 2010 Jun; 117(6):1124-1133.e1. PubMed ID: 20381871
    [Abstract] [Full Text] [Related]

  • 35. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.
    Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A.
    Ophthalmology; 2012 Dec; 119(12):2587-91. PubMed ID: 22902212
    [Abstract] [Full Text] [Related]

  • 36. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery.
    Takamura Y, Kubo E, Akagi Y.
    Ophthalmology; 2009 Jun; 116(6):1151-7. PubMed ID: 19376589
    [Abstract] [Full Text] [Related]

  • 37. Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.
    Gonzalez VH, Boyer DS, Schmidt-Erfurth U, Heier JS, Gordon C, Benz MS, Marcus DM, Sabates NR, Vitti R, Kazmi H, Berliner AJ, Soo Y, Zhu X, Moini H, Zeitz O, Sandbrink R, Do DV.
    Retina; 2015 Apr; 35(4):687-94. PubMed ID: 25621943
    [Abstract] [Full Text] [Related]

  • 38. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study.
    Bonini-Filho M, Costa RA, Calucci D, Jorge R, Melo LA, Scott IU.
    Am J Ophthalmol; 2009 Jun; 147(6):1022-30, 1030.e1-5. PubMed ID: 19327746
    [Abstract] [Full Text] [Related]

  • 39. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema.
    Do DV, Nguyen QD, Shah SM, Browning DJ, Haller JA, Chu K, Yang K, Cedarbaum JM, Vitti RL, Ingerman A, Campochiaro PA.
    Br J Ophthalmol; 2009 Feb; 93(2):144-9. PubMed ID: 19174400
    [Abstract] [Full Text] [Related]

  • 40. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L, Arevalo JF, Berrocal MH, Maia M, Roca JA, Morales-Cantón V, Alezzandrini AA, Díaz-Llopis MJ.
    Retina; 2010 Feb; 30(7):1002-11. PubMed ID: 20616679
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.